甲狀腺癌
甲狀腺癌是一種起源于甲狀腺的惡性腫瘤,甲狀腺位于頸部底部,負(fù)責(zé)生產(chǎn)調(diào)節(jié)新陳代謝的激素。甲狀腺癌的發(fā)病率在全球范圍內(nèi)呈上升趨勢(shì),但其死亡率保持相對(duì)穩(wěn)定,這可能與早期診斷和治療技術(shù)的進(jìn)步有關(guān)。
甲狀腺癌的預(yù)后受多種因素影響,包括病理類型、治療效果和患者的整體健康狀況。乳頭狀癌是最常見(jiàn)的類型,通常預(yù)后較好,而未分化癌和甲狀腺髓樣癌的預(yù)后較差。
甲狀腺癌傳統(tǒng)的治療手段包括手術(shù)、放射性碘治療和甲狀腺素替代治療。對(duì)于晚期或難治性甲狀腺癌,近年來(lái)分子靶向治療和免疫治療的研究取得了顯著進(jìn)展。
- 分子靶向治療:分子靶向治療通過(guò)抑制腫瘤生長(zhǎng)和擴(kuò)散的特定分子通路來(lái)治療癌癥。例如,索拉非尼是第一個(gè)被FDA批準(zhǔn)用于治療進(jìn)展性放射性碘難治性分化型甲狀腺癌(RR-DTC)的分子靶向藥物。此外,RET抑制劑塞爾帕替尼在治療RET突變型甲狀腺髓樣癌(MTC)中表現(xiàn)出顯著的療效。
- 免疫治療:免疫治療通過(guò)激活或增強(qiáng)患者的免疫系統(tǒng)來(lái)攻擊腫瘤細(xì)胞。雖然目前關(guān)于GLP-1RAs和DPP-4i藥物的使用與甲狀腺癌風(fēng)險(xiǎn)之間的關(guān)系仍存在爭(zhēng)議,但免疫檢查點(diǎn)抑制劑等免疫治療方法在甲狀腺癌治療中正受到關(guān)注。
甲狀腺癌藥物靶點(diǎn)
甲狀腺癌藥物靶點(diǎn)相關(guān)產(chǎn)品推薦
● 靶點(diǎn)蛋白
CSB-MP619964HU1

Measured by its binding ability in a functional ELISA. Immobilized PD-1 at 2 μg/ml can bind Anti-PD-1 recombinant antibody, the EC50 of human PD-1 protein is 6.087-7.854 ng/ml.
CSB-MP007763HU

Measured by its binding ability in a functional ELISA. Immobilized HER2 at 2 μg/ml can bind Trastuzumab, the EC50 is 2.179-2.825 ng/ml.
CSB-MP733578HU

Measured by its binding ability in a functional ELISA. Immobilized CD276 at 2 μg/ml can bind Anti-CD276 rabbit monoclonal antibody, the EC50 of human CD276 protein is 1.961-2.243 ng/ml.
CSB-MP005165HU

Measured by its binding ability in a functional ELISA. Immobilized Human CEACAM5 at 2μg/mL can bind Anti-CEACAM5 recombinant antibody (CSB-RA005165MA1HU), the EC50 is 0.8955-1.719 ng/mL.
CSB-MP006163HU1

Measured by its binding ability in a functional ELISA. Immobilized CD152 at 2 μg/ml can bind Anti-CD152 rabbit monoclonal antibody (CSB-RA213310A0HU), the EC50 of human CD152 protein is 27.14-34.82 ng/ml.
CSB-MP882142HU

Measured by its binding ability in a functional ELISA. Immobilized DLL3 at 2 μg/ml can bind Anti-DLL3 Recombinant Antibody(CSB-RA882142A1HU), the EC50 is 1.102-1.707 ng/mL.
CSB-MP007765HU

Measured by its binding ability in a functional ELISA. Immobilized NRG1 (CSB-MP016077HU1(F6)) at 2 μg/ml can bind human ERBB3, the EC50 is 12.32-15.74 ng/ml.
CSB-MP878942HU1

Measured by its binding ability in a functional ELISA. Immobilized PD-L1 at 2 μg/ml can bind Anti- PD-L1 mouse monoclonal antibody(CSB-MA878942A1m, antigen from E.coli), the EC50 of human PD-L1 protein is 1.252-1.653 ng/mL
● 穩(wěn)定細(xì)胞株

HEK293F/Human DLL3 Stable Cell Line
CSB-SC007681HU
Untransfected HEK293 cells (green line) and transfected Human DLL3 HEK293 stable cells (red line) were stained with anti-DLL3 antibody (rovalpituzumab-like) (2μg/1*106 cells), washed and then followed by FITC-conjugated anti-Human IgG1 Fc antibody and analyzed with flow cytometry.
● 重組抗體
CSB-RA005165MA3HU

Overlay Peak curve showing Hela cells surface stained with CSB-RA005165MA3HU (red line) at 1:100.
CSB-RA006163MA1HU

Overlay Peak curve showing JK cells surface stained with CSB-RA006163MA1HU (red line) at 1:50.
CSB-RA882142A1HU

Untransfected HEK293 cells surface (green line) and transfected Human DLL3 HEK293 stable cells surface (red line) were stained with anti-DLL3 antibody (rovalpituzumab-like) (2μl/1*106 cells).
CSB-RA007717MA1HU

Overlay Peak curve showing MCF7 cells surface stained with CSB-RA007717MA1HU (red line) at 1:100.
產(chǎn)品名稱 | 貨號(hào) | 靶點(diǎn) | 反應(yīng)種屬 | 應(yīng)用范圍 |
---|---|---|---|---|
CD274 Recombinant Monoclonal Antibody | CSB-RA977797A0HU | CD274 | Human | ELISA, WB, IHC |
CD274 Recombinant Monoclonal Antibody | CSB-RA878942MA1HU | CD274 | Human | ELISA, IHC, FC |
CD3E Recombinant Monoclonal Antibody | CSB-RA004931MA1HU | CD3E | Human | ELISA, FC |
CEACAM1 Recombinant Monoclonal Antibody | CSB-RA147192A0HU | CEACAM1 | Human | ELISA, IHC |
CEACAM5 Recombinant Monoclonal Antibody | CSB-RA005165MA3HU | CEACAM5 | Human | ELISA, IF, FC |
CEACAM5 Recombinant Monoclonal Antibody | CSB-RA005165MA1HU | CEACAM5 | Human | ELISA |
CTLA4 Recombinant Monoclonal Antibody | CSB-RA213310A0HU | CTLA4 | Human | ELISA, IHC |
CTLA4 Recombinant Monoclonal Antibody | CSB-RA006163MA1HU | CTLA4 | Human, Mouse | ELISA, WB, IF, FC |
DLL3 Recombinant Monoclonal Antibody | CSB-RA882142A1HU | DLL3 | Human | ELISA, FC |
EPCAM Recombinant Monoclonal Antibody | CSB-RA932207A0HU | EPCAM | Human | ELISA, WB |
EPCAM Recombinant Monoclonal Antibody | CSB-RA439934A0HU | EPCAM | Human | ELISA, WB, IHC |
EPCAM Recombinant Monoclonal Antibody | CSB-RA007717MA1HU | EPCAM | Human | ELISA, IHC, FC |
ERBB2 Recombinant Monoclonal Antibody | CSB-RA260392A0HU | ERBB2 | Human | ELISA, IHC, IF |
ERBB2 Recombinant Monoclonal Antibody | CSB-RA007763MA1HU | ERBB2 | Human | ELISA |
Phospho-ERBB2 (Y1139) Recombinant Monoclonal Antibody | CSB-RA588766A0HU | ERBB2 | Human | ELISA, IHC, IF |
ERBB2 Recombinant Monoclonal Antibody | CSB-RA007763MA2HU | ERBB2 | Human | ELISA, IHC |
ERBB3 Recombinant Monoclonal Antibody | CSB-RA937008A0HU | ERBB3 | Human | ELISA, IF |
FAS Recombinant Monoclonal Antibody | CSB-RA252392A0HU | FAS | Human | ELISA, WB, IHC |
ICAM1 Recombinant Monoclonal Antibody | CSB-RA162789A0HU | ICAM1 | Human | ELISA, IHC, FC |
IGF1R Recombinant Monoclonal Antibody | CSB-RA011087MA1HU | IGF1R | Human | ELISA, FC |
PDCD1 Recombinant Monoclonal Antibody | CSB-RA240597A0HU | PDCD1 | Human | ELISA, WB, IHC |
PGF Recombinant Monoclonal Antibody | CSB-RA280380A0HU | PGF | Human | ELISA, IHC |
TOP1 Recombinant Monoclonal Antibody | CSB-RA792129A0HU | TOP1 | Human | ELISA, WB, IHC, FC, IP |